Logo image of AKRO

AKERO THERAPEUTICS INC (AKRO) Stock Fundamental Analysis

NASDAQ:AKRO - Nasdaq - US00973Y1082 - Common Stock - Currency: USD

42.12  -1.55 (-3.55%)

After market: 42.12 0 (0%)

Fundamental Rating

2

Overall AKRO gets a fundamental rating of 2 out of 10. We evaluated AKRO against 572 industry peers in the Biotechnology industry. While AKRO seems to be doing ok healthwise, there are quite some concerns on its profitability. AKRO has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year AKRO has reported negative net income.
AKRO had a negative operating cash flow in the past year.
In the past 5 years AKRO always reported negative net income.
In the past 5 years AKRO always reported negative operating cash flow.
AKRO Yearly Net Income VS EBIT VS OCF VS FCFAKRO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 -50M -100M -150M

1.2 Ratios

AKRO has a better Return On Assets (-29.02%) than 68.94% of its industry peers.
AKRO has a better Return On Equity (-32.13%) than 76.61% of its industry peers.
Industry RankSector Rank
ROA -29.02%
ROE -32.13%
ROIC N/A
ROA(3y)-36.37%
ROA(5y)-33.96%
ROE(3y)-40.75%
ROE(5y)-37.37%
ROIC(3y)N/A
ROIC(5y)N/A
AKRO Yearly ROA, ROE, ROICAKRO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 -200 -400 -600 -800 -1K

1.3 Margins

AKRO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AKRO Yearly Profit, Operating, Gross MarginsAKRO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023

More info and screens

5

2. Health

2.1 Basic Checks

AKRO has more shares outstanding than it did 1 year ago.
AKRO has more shares outstanding than it did 5 years ago.
AKRO has a worse debt/assets ratio than last year.
AKRO Yearly Shares OutstandingAKRO Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M
AKRO Yearly Total Debt VS Total AssetsAKRO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M 500M

2.2 Solvency

An Altman-Z score of 24.05 indicates that AKRO is not in any danger for bankruptcy at the moment.
AKRO has a Altman-Z score of 24.05. This is amongst the best in the industry. AKRO outperforms 94.94% of its industry peers.
AKRO has a Debt/Equity ratio of 0.05. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of AKRO (0.05) is worse than 61.43% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Altman-Z 24.05
ROIC/WACCN/A
WACCN/A
AKRO Yearly LT Debt VS Equity VS FCFAKRO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 0 200M 400M

2.3 Liquidity

A Current Ratio of 17.25 indicates that AKRO has no problem at all paying its short term obligations.
With an excellent Current ratio value of 17.25, AKRO belongs to the best of the industry, outperforming 92.84% of the companies in the same industry.
AKRO has a Quick Ratio of 17.25. This indicates that AKRO is financially healthy and has no problem in meeting its short term obligations.
AKRO has a Quick ratio of 17.25. This is amongst the best in the industry. AKRO outperforms 92.84% of its industry peers.
Industry RankSector Rank
Current Ratio 17.25
Quick Ratio 17.25
AKRO Yearly Current Assets VS Current LiabilitesAKRO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M 500M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for AKRO have decreased strongly by -59.57% in the last year.
EPS 1Y (TTM)-59.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-47.89%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, AKRO will show a very strong growth in Earnings Per Share. The EPS will grow by 20.46% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-39.31%
EPS Next 2Y-29.41%
EPS Next 3Y-20.43%
EPS Next 5Y20.46%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
AKRO Yearly Revenue VS EstimatesAKRO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B 2B
AKRO Yearly EPS VS EstimatesAKRO Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 -4 6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for AKRO. In the last year negative earnings were reported.
Also next year AKRO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AKRO Price Earnings VS Forward Price EarningsAKRO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AKRO Per share dataAKRO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5

4.3 Compensation for Growth

AKRO's earnings are expected to decrease with -20.43% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-29.41%
EPS Next 3Y-20.43%

More info and screens

0

5. Dividend

5.1 Amount

AKRO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AKERO THERAPEUTICS INC

NASDAQ:AKRO (3/7/2025, 8:04:26 PM)

After market: 42.12 0 (0%)

42.12

-1.55 (-3.55%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-08 2024-11-08/bmo
Earnings (Next)03-13 2025-03-13/amc
Inst Owners89.04%
Inst Owner Change4.42%
Ins Owners1.79%
Ins Owner Change2.4%
Market Cap3.35B
Analysts85.56
Price Target79.76 (89.36%)
Short Float %7.34%
Short Ratio3.49
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-1.16%
Min EPS beat(2)-13.96%
Max EPS beat(2)11.64%
EPS beat(4)2
Avg EPS beat(4)-1.9%
Min EPS beat(4)-13.96%
Max EPS beat(4)11.64%
EPS beat(8)5
Avg EPS beat(8)7.01%
EPS beat(12)7
Avg EPS beat(12)3.61%
EPS beat(16)9
Avg EPS beat(16)4.16%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)19.76%
PT rev (3m)62.24%
EPS NQ rev (1m)0%
EPS NQ rev (3m)2.34%
EPS NY rev (1m)-0.04%
EPS NY rev (3m)3.38%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 4.54
P/tB 4.54
EV/EBITDA N/A
EPS(TTM)-3.75
EYN/A
EPS(NY)-4.77
Fwd EYN/A
FCF(TTM)-2.67
FCFYN/A
OCF(TTM)-2.66
OCFYN/A
SpS0
BVpS9.27
TBVpS9.27
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -29.02%
ROE -32.13%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-36.37%
ROA(5y)-33.96%
ROE(3y)-40.75%
ROE(5y)-37.37%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 17.25
Quick Ratio 17.25
Altman-Z 24.05
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-59.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-47.89%
EPS Next Y-39.31%
EPS Next 2Y-29.41%
EPS Next 3Y-20.43%
EPS Next 5Y20.46%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-97.38%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-83.22%
EBIT Next 3Y-35.27%
EBIT Next 5Y22.39%
FCF growth 1Y-126.94%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-125.87%
OCF growth 3YN/A
OCF growth 5YN/A